OXT and Dyspareunia: The meta-analysis results indicate that vaginal oxytocin does not have a significant effect on genitourinary syndrome of menopause (GSM) patients in terms of the vaginal maturation index, vaginal pH, histological evaluation, endometrial thickness, and dyspareunia.